EyePoint Settles DEXYCU Kickback Allegations for $4.7M, Enters 5-Year Corporate Integrity Agreement
EYPT sits 41% above its 52-week low of $9.4.
Summary
EyePoint settled DOJ allegations of kickbacks to ASCs for DEXYCU sales with a $4.7M payment and a 5-year Corporate Integrity Agreement, adding compliance costs and oversight.
Key Events · Legal and Risk Events · EYPT
-
Settlement Reached
EyePoint agreed to pay $4.68M plus interest and $166.5K in attorneys' fees to resolve False Claims Act allegations related to DEXYCU marketing practices from 2019-2023.
-
Corporate Integrity Agreement
A 5-year CIA with OIG-HHS requires a compliance officer, board oversight, an independent review organization, and monitoring of promotional activities, adding operational costs and regulatory risk.
-
Admitted Conduct
EyePoint acknowledged providing free DEXYCU samples and reimbursements to ASCs that may have induced claims to federal healthcare programs, though it denies liability.
-
Financial Impact
The $4.7M settlement is payable within 14 days; the CIA's compliance costs are unquantified but could be material over five years.
Analysis · EYPT · Industrial Applications And Services
EyePoint resolved a False Claims Act investigation into its DEXYCU marketing practices with a $4.7 million settlement and a five-year Corporate Integrity Agreement with the OIG-HHS. The settlement avoids protracted litigation but imposes significant compliance obligations, including an independent review organization, board oversight, and monitoring of promotional activities. While the financial cost is modest relative to EyePoint's $1.1 billion market cap, the CIA's operational burden and the admission of kickback-related conduct could raise governance concerns and distract management during a critical period for its DURAVYU pipeline.
At the time of this filing, EYPT was trading at $13.30 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $9.40 to $19.11. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.